| Name | Title | Contact Details |
|---|
Covers a range of chronic conditions— impacting over 50% of employees Type 2 DiabetesPrediabetesClinical ObesityNAFLD
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.
OMBS is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Union Health Service, Inc. is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Vasade Biosciences is a Long Beach Township, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.